Quince Therapeutics

Quince Therapeutics is a late-stage biotechnology company in South San Francisco developing therapies for rare diseases using a patient's own red blood cells as the drug carrier. Its proprietary AIDE (Autologous Intracellular Drug Encapsulation) platform is a drug-device combination that encapsulates a drug inside the patient's own erythrocytes, aiming to preserve efficacy while reducing the systemic toxicity of chronic corticosteroid use. The lead asset, eDSP, is dexamethasone sodium phosphate encapsulated in autologous red blood cells, and completed the Phase 3 NEAT trial in Ataxia-Telangiectasia in January 2026 without meeting its primary efficacy endpoint. The company trades on the Nasdaq Global Market under the symbol QNCX and was formerly known as Cortexyme, Inc.

The AIDE platform loads a drug into the patient's own red blood cells, which the company positions as offering better tolerability, improved tissue distribution and reduced immunogenicity than conventional systemic dosing of the same corticosteroid.